New drugs that may be approved by the US FDA in December
Active ingredient: Lerodalcibep
Indications: primary hyperlipidemia, atherosclerotic cardiovascular disease (ASCVD)
Company Name: LIB Therapeutics
Lerodalcibep is a PCSK9 targeted inhibitor with long-term stability at room temperature. Its development aims to provide patients with a more convenient, monthly, and self subcutaneous injection treatment plan. In terms of molecular type, Lerodalcibep is a small binding protein (SBP), and its PCSK9 targeted binding domain is an engineered peptide that can bind to human PCSK9 protein with high affinity at the sub nanomolar level. In addition, by fusing with human serum albumin (HSA), lerodalcibep significantly prolongs its plasma half-life, reaching 12-15 days.
Active ingredient: Etripamil
Indication: Paroxysmal supraventricular tachycardia (PSVT)
Company Name: Milestone Pharmaceuticals
Etripamil is a fast acting non dihydropyridine L-type calcium channel blocker (CCB) developed by Milestone Pharmaceuticals for the treatment of PSVT and other arrhythmias. As a nasal spray, etripamil nasal spray can be administered by patients themselves at any time and anywhere, which is expected to transfer the treatment methods currently available in emergency to home and provide faster treatment methods for patients. In May 2021, Jixing Pharmaceutical reached an exclusive license and cooperation agreement with Milestone, obtaining exclusive rights to develop and commercialize etrapamil in Greater China.
Active ingredient: Reproxalap
Indication: Dry Eye Disease (DED)
Company name: AbbVie, Aldeyra Therapeutics
Reproxalap is a potential "first in class" under development small molecule active aldehyde inhibitor. The content of active aldehydes can increase during eye or systemic inflammation, causing eye inflammation, decreased tear secretion, redness of the eyes, and changes in the lipid composition of tears. Many patients with dry eye syndrome have high levels of active aldehydes.
Active ingredient: Depemokimab
Indications: Eosinophilic asthma, chronic sinusitis with nasal polyps
Company Name: GSK
Depemokimab is an under development ultra long acting biological product targeting interleukin-5 (IL-5). Depemokimab can bind with IL-5 with high affinity and is administered every six months to treat severe asthma patients. IL-5 is a key cytokine in type 2 inflammation. More than 80% of severe asthma patients are caused by type 2 inflammation, with elevated levels of eosinophils and unpredictable deterioration of the condition.
Active ingredient: Narsoplimab
Indication: Thrombotic microvascular disease associated with hematopoietic stem cell transplantation (TA-TMA)
Company Name: Omros
Narsoplimab (also known as OMS721) is a fully human monoclonal antibody targeting MASP-2, which acts as an effector enzyme in the complement lectin pathway and is an innovative pro-inflammatory protein target. It is worth noting that inhibiting MASP-2 has been shown to preserve the complete function of the antibody dependent classical complement activation pathway, which is a key component of acquired immune response. The FDA has granted the drug breakthrough therapy designation and orphan drug status for TA-TMA. The European Medicines Agency (EMA) has also approved its orphan drug qualification for hematopoietic stem cell transplantation treatment.
Active ingredient: Aficamten
Indication: Obstructive hypertrophic cardiomyopathy (HCM)
Company Name: Cytokinetics
Aficamten is an under development and potential "best in class" selective small molecule cardiac myosin inhibitor. Aficamten aims to reduce the number of active actin myosin cross-linking bridges in each cardiac cycle, thereby inhibiting excessive myocardial contractions associated with HCM. In preclinical models, aficamten reduces myocardial contractility by directly binding to a unique selective conformational binding site on cardiac myosin, thereby preventing myosin from entering a force producing state. Aficamten has been granted breakthrough therapy recognition by the US FDA and China National Medical Products Administration (NMPA) for the treatment of symptomatic obstructive HCM.
Active ingredient: Relacorilant
Indication: Endogenous hypercortisolism (Cushing's syndrome)
Company Name: Corcept Therapeutics
Relacorilant is an oral, potentially "first in class" selective glucocorticoid receptor (GR) antagonist that regulates cortisol activity by binding to GR rather than other hormone receptors in the body. This therapy has been granted orphan drug status by both the FDA and the European Commission for the treatment of hypercortisolism, and has been granted orphan drug status by the European Commission for the treatment of ovarian cancer.
Active ingredient: Zoliflodacin
Indication: Simple gonorrhea
Company Name: Innoviva Specialty Therapeutics
Zoliflodacin is a potential "first in class" spiropyrimidinethione oral antibiotic with a unique mechanism of action. It can inhibit a key bacterial enzyme called type II topoisomerase, which is crucial for bacterial function and reproduction. Previous in vitro studies have shown that it is active against multidrug-resistant strains of Neisseria gonorrhoeae, including strains resistant to ceftriaxone and azithromycin, and does not develop cross resistance with other antibiotics.







